The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALBT | -76.11% | -99.57% | -66.34% | -99% |
| S&P | +16.07% | +84.26% | +13% | +215% |
Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties. The Medical Related Consulting segment relates to labor and related benefits, travel expenses, and related to consulting services. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
No news articles found for Avalon GloboCare.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $350.10K | 1.4% |
| Gross Profit | $115.73K | 16.2% |
| Gross Margin | 33.06% | 4.2% |
| Market Cap | $9.13M | 3906.8% |
| Market Cap / Employee | $1.83M | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | -$254.27K | 84.9% |
| EBITDA | -$16.73K | 97.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $333.93K | -67.4% |
| Accounts Receivable | $87.32K | 12.4% |
| Inventory | 0.1 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.80K | -99.0% |
| Short Term Debt | $7.23M | 4.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -131.94% | -72.4% |
| Return On Invested Capital | -125.36% | 25.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,546.44K | 5.7% |
| Operating Free Cash Flow | -$1,546.44K | 5.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.24 | -0.42 | -0.28 | -0.29 | 1742.31% |
| Price to Sales | 3.35 | 5.70 | 4.32 | 6.94 | 4618.00% |
| Price to Tangible Book Value | -0.24 | -0.42 | -0.28 | -0.29 | -87.54% |
| Enterprise Value to EBITDA | -31.17 | -12.65 | -6.91 | -1746.89 | 4576.76% |
| Return on Equity | -132.6% | -109.2% | -834.0% | -4165.6% | 3132.84% |
| Total Debt | $7.84M | $8.26M | $8.32M | $7.25M | -16.85% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
